Results 101 to 110 of about 24,353 (179)

A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia

, 2012
Data source: Supplementary data, https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/dds390#supplementary-dataGain-of-function mutations in fibroblast growth factor receptor-3 (FGFR3) lead to several types of human skeletal dysplasia syndromes ...
Yu, Y., Liu, P., Shen, Y., Wang, Q., Xian, C., Deng, C., Qi, H., Tan, Q., Xie, Y., Su, N., Luo, F., Du, X., Chen, L., Jin, M., Wang, X., Huang, H., Zhu, Y., Chen, D.   +17 more
core   +1 more source

Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer

European Urology Open Science
Background and objective: Our aim was to provide a comprehensive analysis of the prevalence of potentially targetable activating FGFR3 alterations and their impact on oncological outcomes across different urothelial carcinoma (UC) stages.
Maximilian Haas, Roman Mayr, Danijel Sikic, Bernd Wullich, Niklas Klümper, Philipp Erben, Ralph Wirtz, Christian Bolenz, Florian Roghmann, Robert Stöhr, Veronika Bahlinger, Arndt Hartmann, Maximilian Burger, Johannes Breyer, Markus Eckstein   +14 more
doaj   +1 more source

No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer

, 2009
Mutations in the fibroblast growth factor receptor 3 (FGFR3) gene causing constitutive oncogenic protein activation have been shown to be frequent in papillary noninvasive bladder tumours and are associated with a low risk of progression and a favourable
Hartmann, Arndt, Otto, Wolfgang, Wild, P J, Peter J. Wild, Andreas Gaumann, Bertz, Simone, Hartmann, A, Bertz, S, Wild, Peter J., Stoehr, R, Gaumann, Andreas, Otto, W, Denzinger, S, Robert Stoehr, Gaumann, A, Arndt Hartmann, Wolfgang Otto, Stefan Denzinger, Denzinger, Stefan, Stoehr, Robert, Simone Bertz   +20 more
core   +1 more source

Fibroblast growth factor receptor 3 mutation promotes HSPB6-mediated cuproptosis in hypochondroplasia by impairing chondrocyte autophagy

Journal of Orthopaedic Translation
Background: Hypochondroplasia (HCH) is a prevalent form of dwarfism linked to mutations in the fibroblast growth factor receptor 3 (FGFR3) gene, causing missense alterations.
Jing Chen, Dan He, Chengrun Yuan, Na Li, Baohong Shi, Conway Niu, Jiangfei Yang, Liangkai Zheng, Lin Che, Ren Xu   +9 more
doaj   +1 more source

Effects ofFGFR3 andPIK3CAmutations on prognosis of bladder carcinoma

Zhongguo aizheng zazhi, 2019
Background and purpose: Alterations in fibroblast growth factor receptor 3 (FGFR3) and phosphoinositide 3 kinase catalytic alpha polypeptide (PIK3CA) have been implicated in the pathogenesis of various carcinomas.
ZHONG Jian, JIN Zhengxian, BIAN Weixing, QIU Jiaxing, HOU Jianquan   +4 more
doaj  

TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia

Achondroplasia (ACH) and hypochondroplasia (HCH), the two most common types of dwarfism, are each caused by FGFR3 gain-of-function mutations that result in increased FGFR3 signaling, which disrupts chondrogenesis and osteogenesis, resulting in ...
Geneviève Baujat, My Chouinard, Michael B. Bober, Ronald V. Swanson, Laurence Legeai-Mallet, Chantal Fayad, Nabil Kaci, Todd Harris, Eric L. Allen, Melissa Neal, Jacqueline H. Starrett, Robert L. Hudkins, Emily A. Pettitt, Melissandre Pache, Matthias Guillo, Qing Ye, Clara Lemoine   +16 more
core   +1 more source

FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma

Pharmacological Research
Dysregulation of fibroblast growth factor receptor (FGFR) signaling contributes to tumorigenesis and FGFRs have been clinically approved as treatment targets for FGFR inhibitor (FGFRi) in urothelial carcinoma (UC).
Yuxuan Song, Shan Jiang, Yun Peng, Yiqing Du, Caipeng Qin, Tao Xu   +5 more
doaj   +1 more source

Characterization of the FGFR3 regulatory network in bladder cancer

, 2020
Le cancer de la vessie est le quatrième cancer le plus fréquent chez les hommes en Europe et lorsque la tumeur envahit le muscle vésical (TVIM), le pronostic est très péjoratif. Or, la prise en charge thérapeutique et la survie des patients atteints d’un
Moreno Vega, Aura Ileana
core  

AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer

Nature Communications
Pathogenic activating mutations in the fibroblast growth factor receptor 3 (FGFR3) drive disease maintenance and progression in urothelial cancer. 10–15% of muscle-invasive and metastatic urothelial cancer (MIBC/mUC) are FGFR3-mutant. Selective targeting
Pierre-Antoine Bannier, Charlie Saillard, Philipp Mann, Maxime Touzot, Charles Maussion, Christian Matek, Niklas Klümper, Johannes Breyer, Ralph Wirtz, Danijel Sikic, Bernd Schmitz-Dräger, Bernd Wullich, Arndt Hartmann, Sebastian Försch, Markus Eckstein   +14 more
doaj   +1 more source

FGFR3-TACC3 fusion transcript detection by RT-PCR.

, 2016
(A) Schematic representation of FGFR3-TACC3 fusion mRNA and PCR primers position. (B) Agarose gel separation of the FGFR3-TACC3 fusion specific RT-PCR amplicons. (C) Sanger sequencing chromatogram of FGFR3-TACC3 fusion specific RT-PCR products.
Hiroshi Tsuruta (3387065), Masahiro Kurobe (3387050), Mikio Sugimoto (3387062), Yuichi Iizumi (3387056), Hiroyuki Nishiyama (105359), Takahiro Kojima (2327002), Takayuki Yoshino (616028), Yoshiyuki Kakehi (567218), Tomonori Habuchi (95713), Yoshiyuki Nagumo (3387047), Kouichi Nishimura (3387059), Shuya Kandori (3387068), Takashi Kobayashi (153394), Yoshiyuki Matsui (2211958), Osamu Ogawa (95712), Satoshi Ueno (731209), Takashi Kawahara (294168), Koji Mitsuzuka (3387053), Koji Kikuchi (267453), Yoichi Arai (728069), Masakazu Tsutsumi (3387071), Takehiro Oikawa (3387044)   +21 more
core   +1 more source